Education
About Us
Working with TipRanks
Follow Us
Compugen Ltd (CGEN)
NASDAQ:CGEN
CGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $2.66
Previous CloseN/A
Volume276.40K
Average Volume (3M)410.45K
Market Cap
$146.82M
Enterprise Value$52.82M
Total Cash (Recent Filing)$45.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)87.5
Beta2.25
Next Earnings
May 08, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding93,512,985
10 Day Avg. Volume243,298
30 Day Avg. Volume410,453
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.65
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$4.00Price Target Upside154.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Compugen News
PremiumCompany Announcements
Compugen’s 2024 Results Highlight Clinical Progress and Financial Stability
PremiumCompany Announcements
Compugen’s Earnings Call: A Cautiously Optimistic Outlook
PremiumCompany Announcements
Compugen Reports 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
Compugen Ltd. Sets Date for Q4 2024 Financial Results Announcement
PremiumPre-Earnings
Compugen (CGEN) Q4 Earnings Cheat Sheet
PremiumCompany Announcements
Compugen Announces Significant Share Price Increase
PremiumCompany Announcements
Compugen Updates Filing Structure with Bristol Myers Squibb---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company's current valuation reflects increased potential due to seven ongoing Phase 3 trials for the TIGIT x PD-1 bispecific rilvegostomig.
PartnershipsCompugen is eligible for up to $200M in development and commercialization milestones spread across the first two rilvegostomig indications, indicating strong partnership benefits.
Safety ProfileRilvegostomig's strong safety outcomes allow for combination with other toxic therapies, potentially enhancing its therapeutic range.
Bears Say
Financial ReservesCompugen ended the year with $103.3M in cash, equivalents, and short-term investments, which may be considered limited for sustaining long-term trials without additional funding.
Investor AwarenessInvestors are missing the positive data in NSCLC and gastric cancer from Compugen's partner, AZN, which could limit stock appreciation.
---
Ownership Overview
―
Insiders
2.60% Mutual Funds
6.29% Other Institutional Investors
88.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGEN FAQ
What was Compugen Ltd’s price range in the past 12 months?
Compugen Ltd lowest stock price was $1.35 and its highest was $2.66 in the past 12 months.
What is Compugen Ltd’s market cap?
Compugen Ltd’s market cap is $146.82M.
When is Compugen Ltd’s upcoming earnings report date?
Compugen Ltd’s upcoming earnings report date is May 08, 2025 which is in 42 days.
How were Compugen Ltd’s earnings last quarter?
Compugen Ltd released its earnings results on Mar 04, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of $0.032 by -$0.102.
Is Compugen Ltd overvalued?
According to Wall Street analysts Compugen Ltd’s price is currently Undervalued.
Does Compugen Ltd pay dividends?
Compugen Ltd does not currently pay dividends.
What is Compugen Ltd’s EPS estimate?
Compugen Ltd’s EPS estimate is -0.07.
How many shares outstanding does Compugen Ltd have?
Compugen Ltd has 93,512,985 shares outstanding.
What happened to Compugen Ltd’s price movement after its last earnings report?
Compugen Ltd reported an EPS of -$0.07 in its last earnings report, missing expectations of $0.032. Following the earnings report the stock price went down -7.182%.
Which hedge fund is a major shareholder of Compugen Ltd?
Currently, no hedge funds are holding shares in CGEN
---
Compugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (154.78% Upside)
$4.00 (154.78% Upside)
Blogger Sentiment
Bullish
CGEN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.94%
12-Months-Change
Fundamentals
Return on Equity
-23.63%
Trailing 12-Months
Asset Growth
-5.22%
Trailing 12-Months
Company Description
Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
---
CGEN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Compugen's clinical programs, strategic partnerships, and financial stability, which are promising for future growth. However, the company faced revenue declines and a net loss, along with challenges in the TIGIT landscape. Despite these challenges, the strategic advances and strong financial position suggest a cautiously optimistic outlook.Read More>---
CGEN Stock 12 Month Forecast
Average Price Target
$4.00
▲(154.78% Upside)
Technical Analysis
Best Analysts Covering CGEN
1 Year
1 Year Success Rate
4/15 ratings generated profit
1 Year Average Return
-10.69%
reiterated a buy rating 23 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -10.69% per trade.
---